Originally published In Press as doi:10.1074/jbc.M201486200 on March 21, 2002
J. Biol. Chem., Vol. 277, Issue 22, 19792-19799, May 31, 2002
Species-specific Inhibition of Porphobilinogen Synthase by
4-Oxosebacic Acid*
Eileen K.
Jaffe
§,
Jukka
Kervinen
¶,
Jacob
Martins
,
Frédéric
Stauffer
**,
Reinhard
Neier
,
Alexander
Wlodawer
, and
Alexander
Zdanov
From the
Institute for Cancer Research, Fox Chase
Cancer Center, Philadelphia, Pennsylvania 19111, the
Department of Chemistry, University of Neuchatel, Neuchatel
2007, Switzerland, and the 
Macromolecular
Crystallography Laboratory, NCI-Frederick, National Institutes of
Health, Frederick, Maryland 21702
Received for publication, February 13, 2002, and in revised form, March 19, 2002
 |
ABSTRACT |
Porphobilinogen synthase (PBGS) catalyzes the
condensation of two molecules of 5-aminolevulinic acid (ALA), an
essential step in tetrapyrrole biosynthesis. 4-Oxosebacic acid (4-OSA)
and 4,7-dioxosebacic acid (4,7-DOSA) are bisubstrate reaction
intermediate analogs for PBGS. We show that 4-OSA is an active
site-directed irreversible inhibitor for Escherichia coli
PBGS, whereas human, pea, Pseudomonas aeruginosa, and
Bradyrhizobium japonicum PBGS are insensitive to inhibition
by 4-OSA. Some variants of human PBGS (engineered to resemble E. coli PBGS) have increased sensitivity to inactivation by 4-OSA,
suggesting a structural basis for the specificity. The specificity of
4-OSA as a PBGS inhibitor is significantly narrower than that of
4,7-DOSA. Comparison of the crystal structures for E. coli
PBGS inactivated by 4-OSA versus 4,7-DOSA shows significant variation in the half of the inhibitor that mimics the second substrate
molecule (A-side ALA). Compensatory changes occur in the structure of
the active site lid, which suggests that similar changes normally occur
to accommodate numerous hybridization changes that must occur at C3 of
A-side ALA during the PBGS-catalyzed reaction. A comparison of these
with other PBGS structures identifies highly conserved active site
water molecules, which are isolated from bulk solvent and
implicated as proton acceptors in the PBGS-catalyzed reaction.
 |
INTRODUCTION |
Porphobilinogen synthase
(PBGS,1 EC 4.2.1.24, also
known as 5-aminolevulinate dehydratase) recently has emerged as a
viable enzyme target for the development of pharmaceuticals or
agricultural agents. The PBGS protein, which is highly conserved in
both sequence and structure (1), catalyzes an early essential step in
the biosynthesis of the tetrapyrrole cofactors such as heme and
chlorophyll (Fig. 1A). Despite
the fact that much is known about the PBGS structure, the sequence of
bond-making and bond-breaking events that follow formation of the
ternary complex of PBGS with the two substrate molecules is the subject
of active discussion (2-5). Based on an extensive phylogenetic
variation in the number and kinds of metal ions used for catalytic
and/or allosteric roles, it is possible that the order of chemical
events in the enzyme-catalyzed reaction mechanism may not be
phylogenetically conserved. In order to probe the mechanism,
4,7-dioxosebacic acid (4,7-DOSA) and 4-oxosebacic acid (4-OSA),
illustrated in Fig. 1B, were designed and found to act as
suicide substrates for Escherichia coli PBGS (6). These
inhibitors mimic an addition product intermediate in which the first
bond formed between the two 5-aminolevulinic acid (ALA) substrate
molecules creates a carbinolamine that dehydrates to a Schiff base (6).
More recently, a strong species-selective inhibition of PBGS by
4,7-DOSA has been correlated with an active site variation in metal ion
usage (3). Here we have characterized a very different species
selectivity for 4-OSA inhibition of PBGS and provide a 1.9-Å crystal
structure of 4-OSA-inhibited E. coli PBGS. This structure
was compared with an improved 1.7-Å crystal structure of
E. coli PBGS inhibited by 4,7-DOSA and with analogous structures of these inhibitors bound to yeast PBGS (for which, however,
there are no kinetic inhibition data) (5).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
PBGS-catalyzed reaction and
bisubstrate/intermediate site-directed inhibitors. A,
PBGS catalyzes the first common step in the biosynthesis of the
tetrapyrroles. The chemistry is an asymmetric condensation of two
molecules of ALA. A-side ALA contributes the acetyl side chain and
retains a free amino group. P-side ALA (bold bonds,
italic) contributes the propionyl side chain and has its
amino group incorporated into the pyrrole ring. B, the PBGS
inhibitors 4,7-DOSA and 4-OSA both mimic a putative reaction
intermediate wherein C4 of A-side ALA forms a Schiff base with the C5
amino group derived from P-side ALA.
|
|
 |
EXPERIMENTAL PROCEDURES |
Materials--
Most chemicals and buffers were obtained from
Fisher or Sigma in the purest available form. 2-Mercaptoethanol
(
ME) from Fluka (Buchs, Switzerland) was vacuum-distilled prior to
use. 4-OSA and 4,7-DOSA were synthesized and tested (as
described in Ref. 6). All of the PBGS enzymes used in this study were
cloned and expressed in E. coli, and purification and
detailed characterization has been described previously (7-12). Human
PBGS was the C162A variant of the natural N59 isozyme, and it has
kinetic properties closely resembling the wild type (13). Human PBGS
mutants characterized with 4-OSA were N59/C162A/H131A/C223A
(called MinusZnA) (13) and two new chimeric proteins (Hs
ALK and
HsEclid) containing portions of the E. coli PBGS active site
lid. The chimeric proteins were prepared from the plasmid encoding wild
type human PBGS variant N59/C162A by the QuikChange method of
mutagenesis. The sense strand primers were
CCGTTCCGTGATGCGCTAAGTCAGCATTAAAAGGCGACCGCCGCTGC for Hs
ALK and
CCGTTCCGTGAAGCTGCTGGGTCAGCCTTAAAAGGCGACCGCAAAGCTATCAG for HsEclid.
Activity Assays for PBGS--
The enzyme assay measures the
formation of porphobilinogen from ALA. The assay conditions at optimal
pH and with a full complement of required and allosteric metal ions in
the standard 5-min assay procedure for each of the five PBGS were
performed as described previously (3). Human mutants MinusZnA,
Hs
ALK, and HsEclid were assayed in the same fashion as the wild
type. To ensure reliable A555 values, assays of
low specific activity mutants used a 30-min incubation with substrate.
Enzyme concentrations were measured with Coomassie Plus protein assay
reagent (Pierce) relative to a standard curve prepared with bovine
serum albumin.
Inhibition of PBGS by 4-OSA--
The five species of PBGS (1 µM subunit) were preincubated under optimal assay
conditions for 10 min at 37 °C prior to the addition of 4-OSA over
the concentration range of 10 µM to 3 mM; preincubation was allowed to proceed for various times ranging from 90 min to 22 h at 37 °C before initiating the formation of porphobilinogen by addition of ALA-HCl to a final concentration of 10 mM. Porphobilinogen formation was allowed to proceed for 5 min. For E. coli PBGS, 4-OSA inhibition data were fitted to the equation v/vo = 1/(1+([I]/IC50))
(14) using the program SigmaPlot (SPSS®, Chicago, IL). For other
species of PBGS the apparent IC50 values for 4-OSA were
well above millimolar concentrations and the 10 µM-3 mM inhibition data could not be fit
well. In these cases a simple direct comparison of the five species
used a 4-OSA concentration of 3 mM and a 24-h
enzyme/inhibitor incubation time prior to the addition of ALA.
Crystallization of E. coli PBGS Complexed with 4,7-DOSA and 4-OSA
and Structure Solution--
Crystallizations were carried out with
both 4-OSA and 4,7-DOSA as described previously for 4,7-DOSA (3). In
both cases, E. coli PBGS (9 mg ml
1 in 50 mM Tris-HCl, pH 8.0, 10 mM
ME, 20 µM ZnCl2, 10 mM
MgCl2) was incubated for 24 h at 37 °C with a
16-fold molar excess of the inhibitor (~4 mM) prior to
setting up the crystallization trays. An equal volume of clarified
protein was mixed with reservoir buffer containing 1-6% polyethylene
glycol 3350, 10% glycerol, 0.1 M Tris-HCl, pH 8.5, and
0.02% sodium azide. The crystals with a diamond-like shape appeared in
1-3 days, and the largest crystals grew to their final size (up to
0.6 × 0.6 × 0.3 mm3) in approximately 2 weeks.
Cryoprotection was carried out by transferring a crystal to reservoir
solutions containing 17, 23, and 30% glycerol, respectively (3 min in
each solution), and the crystal was flash-frozen in a liquid nitrogen
vapor. X-ray diffraction data for both complexes were collected from
one crystal at 100 K using a QUANTUM-4 CCD detector mounted at
synchrotron beamline X9B at Brookhaven National Synchrotron Light
Source facility. The data sets consisted of 180 frames chosen to cover
at least one asymmetric unit with each frame corresponding to 0.5°
oscillation exposed for 35 s. Crystals belong to a tetragonal
system, space group, P4212; unit cell parameters, a = b = 129.0 Å, and c = 142.8 Å with two molecules per
asymmetric unit. Diffraction intensities were processed with the
HKL2000 suite of programs (15), resulting in final data sets with
Rmerge(I) = 5.1 and 5.6% for 126,253 and 92,714 independent reflections and with completeness of 95.7 and 99.8%
for the 40-1.7 and 40-1.9 Å resolution range for 4,7-DOSA and 4-OSA
complexes, respectively.
Because the crystals were in both cases isomorphous to that of E. coli PBGS complexed with 4,7-DOSA (PDB entry 1I8J), rigid body
refinement of the PBGS dimer against the corresponding diffraction data
was sufficient to properly orient the protein model in the respective
crystal unit cell. Refinement was carried out with program package CNS
(16) with weak non-crystallographic symmetry restraints corresponding
to weight 25. Model building was performed with program O (17). The
final models included one dimer of PBGS molecule complexed with two
respective inhibitor molecules, 498 and 433 water molecules for
4,7-DOSA and 4-OSA, respectively, as well as two Zn2+ and
two Mg2+ ions. Five glycerol molecules were found in the
4-OSA structure. The crystallographic R-factors were 19.5 and 20.6%, R(free) parameters were 24.3 and
26.3% for the 1.7- and 1.9-Å resolution data, and the RMS deviations
for bond lengths and bond angles were 0.018 Å and 1.8° for 4,7-DOSA
and 0.019 Å and 2.0° for 4-OSA, respectively. The coordinates have
been deposited in the Protein Data Bank with the PDB codes 1L6S and
1L6Y for immediate release.
 |
RESULTS |
Kinetic Evaluation of the Inhibition of PBGS Enzymes by
4-OSA--
The inactivation of PBGS by 4,7-DOSA was shown previously
to be dependent both upon the concentration of the inhibitor and the
preincubation time of the inhibitor and enzyme prior to addition of
substrate (3). This is also true for 4-OSA, which was a less potent
inactivator than 4,7-DOSA. Fig.
2A illustrates the time and
concentration dependence for the interaction of 4-OSA with E. coli PBGS using enzyme/inhibitor incubation times of 94 min and
16 h and 4-OSA concentrations from 10 µM to 3 mM. For comparison we also included data from a comparable
100-min incubation of E. coli PBGS in which 4,7-DOSA was the
inhibitor (3). These data indicate that 4-OSA is far less potent
against E. coli PBGS than is 4,7-DOSA, consistent with prior
reports (6). Using the approximation of Copeland et
al. (14), the IC50 values for E. coli
PBGS inhibition by 4-OSA at 94 min and 16 h are 0.57 ± 0.06 mM and 0.22 ± 0.01 mM, respectively. The
IC50 for 4,7-DOSA at 100 min of incubation with E. coli PBGS is 0.039 ± 0.002 mM. The reduced
sensitivity to 4-OSA relative to 4,7-DOSA is also true for human,
Bradyrhizobium japonicum, Pseudomonas aeruginosa, and Pisum sativum (pea) PBGS, where a similar experiment
showed marginal if any inactivation by 4-OSA across the range of 10 µM to 3 mM 4-OSA. To compare the five
species, Fig. 2B illustrates a 24-h preincubation of 3 mM 4-OSA with all five PBGS and shows a high selectivity
for inactivation of E. coli PBGS. The control reactions
wherein inhibitor was omitted did not lose any significant activity.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 2.
Inactivation of PBGS by 4-OSA.
A, inactivation of E. coli PBGS by 4-OSA
(circles) relative to previously published data for 4,7-DOSA
(squares) (3). Enzyme incubation times (prior to addition of
substrate) are 94-100 min for the filled symbols and
16 h for the open symbols. Lines are best
fit to the equation v/vo = 1/[1+([I]/IC50)]
(14). B, inactivation of a family of wild type PBGS enzymes
by 3 mM 4-OSA using a fixed 24-h inhibitor/enzyme
incubation time prior to activity assay. The species are E. coli (Ec), human (Hs), B. japonicum (Bj), P. aeruginosa
(Pa), and P. sativum L. (Ps). For
these determinations, the protein concentrations were all at 1 µM subunit. C, inactivation of mutant or
chimeric PBGS by 3 mM 4-OSA using a 24-h enzyme/inhibitor
incubation time. The bars correspond to E. coli
(Ec), human (Hs), human MinusZnA ( ZnA),
Hs ALK, and HsEclid.
|
|
Evaluation of 4-OSA with Mutant Forms of Human PBGS--
The high
selectivity of 4-OSA inactivation for E. coli PBGS is in
sharp contrast to the species selectivity of inactivation by 4,7-DOSA
(3). The latter showed a marked preference for the
Zn2+-utilizing PBGS and was highly effective against human
PBGS, which contains two different types of Zn2+ binding
sites. In that case, evaluation of an active human PBGS mutant
(MinusZnA) that lacked the nonessential Zn2+ showed reduced
sensitivity to 4,7-DOSA. Of the five species evaluated, only human and
E. coli PBGS use a catalytic Zn2+. Because the
number and types of Zn2+ sites are a significantly
different between human and E. coli PBGS, this MinusZnA
human PBGS was also evaluated with 4-OSA, and the results are included
in Fig. 2C. Consistent with the notion that MinusZnA is more
like E. coli PBGS, MinusZnA retains only ~65% activity
after a 22-h incubation with 3 mM 4-OSA. Thus, MinusZnA is
significantly more sensitive to inactivation by 4-OSA than is human
PBGS, but it remains far less sensitive than E. coli PBGS.
In search for the structural basis for the high selectivity of 4-OSA
against E. coli PBGS, we compared the known structures (and
sequences) of the PBGS to define unique features of E. coli PBGS. One significant variable feature in the PBGS family of proteins is the length and sequence of the active site lid. Based on the E. coli PBGS crystal structure, the lid is defined as the
stretch from Ala196 to Gln219. The lid includes
all of the residues in this region that are found to be disordered in
PBGS structures 1AW5, 1B4K, and 1E51. Fig.
3A shows a structure-based
sequence alignment of the active site lid of human, yeast, E. coli, P. aeruginosa, B. japonicum, and
P. sativum PBGS, which is different from previously
published sequence-based alignments. Fig. 3B shows a
color-coded structural overlay of the lid region from PBGS
corresponding to PDB codes 1E51 (human), 1YLV (yeast), 1I8J (E. coli), and 1B4K (P. aeruginosa). E. coli
PBGS is unique among those tested with 4-OSA in that it has the
shortest lid sequence. To evaluate the significance of this variable,
we created, prepared, and characterized two chimeric "lid-switch"
PBGS based on human PBGS using portions of the E. coli lid
sequence.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
Variations in the PBGS active site lid.
A, structure-based sequence alignment of PBGS from human,
yeast, E. coli, P. aeruginosa, B. japonicum, and P. sativum L. showing only the active
site lid. Sequences are included for the variant and chimeric
human PBGS that were evaluated as targets for 4-OSA inhibition. The
region containing the R(X)10-13
R/K(X3)Q sequence forms multiple H-bonding
interactions with the carboxyl group derived from A-side ALA.
The gray background corresponds to the region of
variable sequence length. Sequences in bold are included in
and color-coded to the structure alignment in B. Amino acids
seen to interact with active site ligands are denoted with an
asterisk. B, a stereo view structure alignment
showing the closed-lid conformation of human (black), yeast
(red), E. coli (green), and P. aeruginosa (yellow) PBGS for the sequence region shown
in A.
|
|
The minimal lid switch chimeric protein contains the small portion of
the E. coli lid that varies in backbone structure. The sequence of this variant, called Hs
ALK, is included in Fig.
3A. Hs
ALK is an active PBGS with a specific activity of
~4% of wild type human PBGS and a normal Km
value. Purified Hs
ALK contains 3.5 Zn2+/octamer. As
predicted from its increased sequence similarity with E. coli PBGS, Hs
ALK has increased sensitivity to inhibition by
4-OSA (see Fig. 2C). A less predictable result was observed when a larger portion of the lid sequence was switched. The human PBGS
variant HsEclid contains the E. coli PBGS lid sequence from Arg204 to Gln219 (E. coli numbering)
as illustrated in Fig. 3A. HsEclid is also an active PBGS
with a specific activity of ~12% of wild type human PBGS and a
normal Km value. HsEclid was found to purify with
4.5 Zn2+/octamer. Inconsistent with other human PBGS
variants that are designed to resemble E. coli PBGS, HsEclid
is insensitive to inhibition by 4-OSA (see Fig. 2C). The
human PBGS variant MinusZnA, whose behavior with 4-OSA is described
above, is included in Fig. 3 because one of the mutations (C223A) is in
this active site lid region. The Zn2+ stoichiometry of
Hs
ALK and HsEclid suggests that these human PBGS variants retain the
property of half-site reactivity, a kinetic property that is well
established for human PBGS but not for E. coli PBGS.
E. coli PBGS Crystal Structures with 4-OSA and 4,7-DOSA--
The
PBGS all share a common octameric structure with two monomers forming a
dimer around either the non-crystallographic or crystallographic 2-fold
symmetry axis and four such dimers forming a PBGS octamer around the
4-fold symmetry axis. Each monomer/subunit forms an 
-barrel, the
center of which holds the active site residues, while an N-terminal arm
that varies in length between species is mutually wrapped around the
neighboring subunit forming a compact dimeric structure. The N-terminal
arms are involved in extensive subunit interactions within and between
dimers. Some PBGS crystal structures show an individual subunit as the
asymmetric crystallographic unit, and others (such as those presented
here) show a dimer as the asymmetric unit. A variety of data have been interpreted to indicate that an oligomeric structure is required for
activity (see Ref. 7). Each active site region is confined to one
subunit and isolated from bulk solvent by a lid. The
4,7-DOSA-containing E. coli PBGS was the first structure to
show that the lid-closed configuration involves extensive hydrogen
bonding with the carboxyl group of the A-side ALA molecule, which makes
up the acetyl half of porphobilinogen (see Fig. 1A and
below) (3). The structure is consistent with the notion that P-side
ALA, which makes up the propionyl half of the product, binds
first and that the A-side ALA binds second (see Refs. 18 and 19).
Similar to other 
-barrel enzymes, the ordering and disordering of
the active site lid appears to be essential for substrate binding,
isolation of the active site from bulk solvent, and product release.
The current structures better define these lid motions. The lid
residues seen to interact with active site ligands presented here and
elsewhere are denoted in Fig. 3.
Here we present the crystal structures of E. coli PBGS that
has been inactivated by 4-OSA and of another one that has been inactivated by 4,7-DOSA. The latter structure is the same complex that
we already published (PDB code 1I8J); however, this time resolution of
the diffraction data was extended to 1.7 Å so that we were able to
locate 183 extra water molecules, clarify that both Cys133A
and Cys133B are adducted with
-mercaptoethanol (see
below), and generally provide a more accurate structural description of
the protein and the inhibitors. A major new observation based on this
structure is a significant variation in the position of the inhibitor
half that mimics A-side ALA. Such a result has not been reported for the comparable complex of 4-OSA with yeast PBGS (5). Similar to the
complex of 4,7-DOSA-inhibited PBGS, the 4-OSA-inhibited E. coli PBGS asymmetric unit contains a dimer, and each subunit of
the 4-OSA complex contains one inhibitor molecule, one Zn2+
bound at the active site, and one Mg2+ bound at the
allosteric site (Fig. 4). Unlike the
4,7-DOSA-inhibited PBGS, the 4-OSA complex can form only one Schiff
base linkage between each inhibitor and PBGS subunit; this linkage is
observed. The RMS deviation between the C
atoms of the two monomers
forming a non-crystallographic dimer is 0.25 Å, whereas the RMS
deviation between the 4,7-DOSA- and 4-OSA-inhibited PBGS dimers is 0.24 Å. Thus, we conclude that there are no significant differences between
the monomers of the dimer or the dimers themselves upon binding either
to 4,7-DOSA or 4-OSA (except for part of the lid near
Arg204, described below), although the conformations of
some side chains (mainly those located on the surface of the octamer)
are occasionally different. The average temperature factors are 43.2 and 43.4 Å2 for monomers A and B of the 4-OSA-containing
complex and 30.2 and 31.2 Å2 for monomers A and B of the
4,7-DOSA-containing complex. This indicates that the monomers in each
complex have essentially the same degree of flexibility, although the
crystals of the 4,7-DOSA complex have better internal order. The
symmetry seen in E. coli PBGS dimers is in sharp contrast to
the high resolution asymmetric dimer seen in P. aeruginosa
PBGS (PDB code 1B4K) (20) and the less well resolved human PBGS, which
contains extensive disorder (PDB code 1E51, unpublished structure).

View larger version (66K):
[in this window]
[in a new window]
|
Fig. 4.
A stereo diagram of the 4-OSA inactivated
E. coli PBGS dimer. The two monomers are shown in
blue and magenta, Zn2+ is dark
green, Mg2+ is orange, and the active site
lid is yellow. The two active site lysine residues
are shown (ball-and-stick) with bonds colored according to
the subunit; Lys246 makes Schiff base to atom C4 of the
inhibitor. The 4-OSA molecules are shown (ball-and-stick)
with bonds in green. Atom color code is C, green;
N, blue; O, red.
|
|
The two E. coli PBGS structures presented here clarify
the amino acid identity of position 133, which had previously been identified as a lysine (2). The DNA sequence indicates
Cys133 and mass spectroscopy analysis of an AspN digest was
obtained herein to demonstrate the existence of a cysteine in this
position. Because Cys133 is located on the surface of the
protein, which has been purified and stored in the presence of
mercaptoethanol, this residue appears as an adduct of
ME and
cysteine (S,S-2-(hydroxyethyl)thiocysteine). The
adduct was first reported in a V23C variant of staphylococcal nuclease
(21), and the current electron density is an excellent fit to this model.
Mechanism of Inhibition by 4-OSA and 4,7-DOSA--
The inhibitor
molecules are clearly seen in the difference electron density maps in
the area of the active site next to Lys194 and
Lys246 in both monomers. In the case of 4,7-DOSA there are
two covalent linkages between the protein and the inhibitor, and in the
case of 4-OSA there is one covalent linkage. Fig.
5A illustrates an electron
density map of 4-OSA bound to the enzyme, and Fig. 5B shows
a comparison between the 4-OSA- and 4,7-DOSA-inhibited proteins. In
both cases C1-C5 of the inhibitor are bound with a Schiff base linkage
between C4 and the
-amino group of Lys246. In these
cases, as well as in related PBGS structures with inhibitors bound in
the P-side ALA binding pocket (PDB codes: 1B4E, 1B4K, 1EB3, 1YLV, 1I8J,
1GJP, 1H7N, 1H7P, 1H7R), the C1 carboxyl oxygens of the inhibitor make
hydrogen bonds with Ser272 and Tyr311. The
positions of the C2 and C3 atoms of each inhibitor are well defined but
not equivalent to each other. The variation in these positions mimics
the reported alternate conformations of levulinic acid bound as the
P-side Schiff base to yeast PBGS (PDB code 1H7N) (22). This variation
defines the limited spatial flexibility of P-side ALA and dictates that
these atoms cannot reorient much in response to required hybridization
changes at C4. The position of C1-C4 of 4-OSA more closely resembles
that of the product porphobilinogen. As reported previously for the
1.9-Å structure of 4,7-DOSA-inhibited E. coli PBGS, the
bond between C5 and C6 of the inhibitor has a distorted
cis-configuration (torsion angle of C4-C5-C6-C7 is ~65°) to
accommodate a second Schiff base linkage between C7 and the
-amino
group of Lys194. Because there is no Schiff base to
Lys194 in the 4-OSA-inhibited enzyme, the conformation
around the C5-C6 bond (torsion angle C4-C5-C6-C7 is ~
88°) and
the positions of C5-C10 of reacted 4-OSA are significantly different
from those seen for 4,7-DOSA (Fig. 5B). This suggests that
A-side ALA has much greater positional flexibility than does P-side
ALA. Positional flexibility is essential to accommodate the multiple
hybridization changes required in the formation of porphobilinogen. In
the case of both inhibitors, the A-side ALA half (C8-C10) extends out
toward the lid where it makes extensive hydrogen-bond linkages between the C10 carboxyl oxygens and arginine residue(s). However, the hydrogen-bonding pattern is not the same for the two inhibitors, as
illustrated schematically in Fig. 6.
Unlike 4,7-DOSA, 4-OSA does not interact with Gln219
through hydrogen bonds directly; instead it does so through a bridging
water molecule. This is the same water molecule that forms similar
bridging hydrogen bonds between Gln219 and
Arg204 in the 4,7-DOSA-containing complex. To accommodate
the different structure of the A-side half of the 4-OSA inhibitor, the
side chain of Arg204 moves approximately 2.5 Å away from
the position it occupied in the 4,7-DOSA complex (Fig. 5B)
and is locked in this new position by a hydrogen bond between its side
chain NH1 atom and the carbonyl oxygen of Gly213. The
position of Arg204 in the absence of an A-side ligand
(structure 1B4E) is much like that of the 4,7-DOSA-containing complex,
but its H-bonds are strictly to water. Despite the different position
of the Arg204 side chain in these structures, the C
atoms of this part of the lid (positions 203-205) move <1.4 Å. The
difference in the position and conformation of the A-side of 4-OSA
results in C7 being approximately 1 Å closer to the catalytic
Zn2+; the distance C7-Zn2+ is 4.5 versus 5.5 Å in 4,7-DOSA. There are several ordered water molecules found within a 5-Å distance from the inhibitor in the A-side
of both complexes that are included in Fig. 5. They are all the same in
both structures and are also seen in high resolution structures of
yeast PBGS and P. aeruginosa PBGS.

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 5.
The active sites of 4-OSA and 4,7-DOSA
inactivated E. coli PBGS. A, stereo picture of
the electron density corresponding to 4-OSA, Lys194, and
Lys246 at the active site of the enzyme. Atoms derived from
4-OSA are in magenta; atoms of Lys194 and
Lys246 are black; carbons from protein are
green; nitrogen is blue; oxygen is
red; sulfur is yellow; and Zn2+ is
black. Highly conserved active site water molecules
are included. The illustration shows a 2Fo Fc difference electron density map contoured at
a level of 1.5 . B, stereo overlay of 4,7-DOSA
(blue)-inhibited E. coli PBGS (black)
with 4-OSA (magenta)-inhibited E. coli PBGS
(green).
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Schematic diagram of the hydrogen bonding of
4-OSA (A) and 4,7-DOSA (B) with E. coli
PBGS. The carbon atoms of 4-OSA and 4,7-DOSA are numbered.
Water molecules are represented by single oxygen atoms as O. Dashed lines indicate potential hydrogen bonds
using a heteroatom distance of 3.2 Å. Hydrogen bonds are
depicted for subunits A. In subunit B the
Gly213(O)-Arg204(N), the
4-OSA(O)-Arg204(NE), and the 4-OSA(O)-water(connected to
Gln219) distances are 3.5-3.8 Å. Dotted
lines indicate the Zn2+ ligand bonds, which are each
~2.4 Å.
|
|
 |
DISCUSSION |
4-OSA Bound to PBGS--
The structures presented in Fig.
5B can be compared with recently published crystal
structures of these inhibitors with yeast PBGS (PDB codes 1EB3 and
1GJP) (5). In these structures the A-side of the inhibitor is modeled
such that the carboxyl groups of 4-OSA and 4,7-DOSA are in nearly the
same position as each other. In the case of 4-OSA, we consider this
interpretation questionable because Arg220 (the counterpart
of E. coli Arg204) is shifted 2.6 Å away from
the active site in a manner similar to what is found in the E. coli 4-OSA-inhibited PBGS structure. In the yeast structure, the
dramatically shifted Arg220 does not interact with the
inhibitor or any other atoms except for two water molecules on the
surface of the protein. In fact, 4-OSA of 1GJP is reported as
"somewhat disordered," and the presented electron density map is
completely lacking density for one of the A-site carboxyl oxygens. A
more compelling reason to question the model for 4-OSA bound to yeast
PBGS comes from a comparison of the yeast PBGS structure IGJP
with the E. coli PBGS complex presented here. When one
superimposes the 4-OSA-inhibited E. coli PBGS structure
(where inhibitor was perfectly ordered) with 1GJP (superposition was
based only on the protein parts of the complex), we find that our 4-OSA
inhibitor makes exactly the same hydrogen bonds with the yeast enzyme,
including Arg220 in its new position, as in E. coli 4-OSA PBGS complex. In other words, the structure of 4-OSA as
it is found in the complex with E. coli PBGS is
energetically more favorable upon binding to the yeast enzyme than the
one that was reported in the crystal structure of the complex of 4-OSA
with yeast PBGS itself (5). Taken together, these points shed doubt on
the interpretation of the conformation of 4-OSA bound to yeast PBGS in
structure 1GJP.
The PBGS-catalyzed Reaction Mechanism, Active Site Lid Motion, and
Enzyme-bound Active Site Water--
The PBGS-catalyzed reaction is
illustrated in Fig. 1. The first ALA to bind to PBGS is P-side ALA
(18). P-side ALA forms a Schiff base intermediate to an active site
lysine (Lys246 in E. coli PBGS) (23). Metals are
not required for the binding or reactivity of P-side ALA (19).
Maintenance of the deprotonated Schiff base-forming lysine is
accomplished by the neighboring basic residue (here
Lys194). As with all Schiff base-forming enzymes, one
expects to be able to identify the residue that serves in the removal
of the oxygen atom from the carbinolamine intermediate that precedes P-side Schiff base formation. This residue is not apparent in any PBGS
crystal structures and has not been addressed in prior publications.
The existing PBGS structures all place the P-side Schiff base in a very
hydrophobic environment, part of which is composed of aromatic residues
in the N-terminal portion of the active site lid (see Fig. 5). Because
this Schiff base occurs for both 4-OSA and 4,7-DOSA, and the resulting
water molecule is not observed near the P-side of the inhibitor, we
conclude that this first water molecule must relocate prior to lid
closure. One possible acceptor for the carbinolamine hydroxyl group
would be the protonated Lys194 in a rotomer conformation
different from that which is observed in here. In this case the
reaction would be as shown in Reaction I.
|
|
|
|
|
|
|
|
Alternatively, one may propose that the protonated base
that dehydrates the P-side carbinolamine comes from an alternate configuration of the active site lid. The lid contains many conserved basic residues (see Fig. 3), which (as seen in the structures presented
here) can interact with the A-side carboxyl group later in the reaction
but may serve an additional function earlier.
The second ALA to bind to PBGS is A-side ALA. For those PBGS that use a
catalytic Zn2+, the metal ion is required for A-side ALA
binding and reactivity (19). The crystal structures of 4,7-DOSA- and
4-OSA-inhibited PBGS support the mechanistic hypothesis that the keto
oxygen removed from C4 of A-side ALA (C7 of the inhibitors) ends up
coordinated to the catalytic Zn2+ (3). We have proposed
that A-side ALA binds as a bidentate Zn2+ ligand through
the C4 keto oxygen and the C5 amino group (24). Molecular modeling
studies indicate that this complex fits into the A-side ALA binding
pocket and takes advantage of the unique flexibility of
Zn2+ to accommodate various coordination numbers and
geometries (25). The coordination environment of this Zn2+
is unusual for a catalytic Zn2+ in that it contains three
cysteine ligands that derive from a short stretch of 11 amino acids.
The structures presented here indicate that the Zn2+-bound
water molecule is appropriately positioned to have derived from the
keto group analogous to that of A-side ALA.
Based on the extensive hydrogen-bonding interactions between the A-side
carboxylic acid group of 4-OSA and 4,7-DOSA and the active site lid
residues, we conclude that A-side ALA binding necessitates the ordering
or reordering of the active site lid. Comparison of the conformation of
the lid between the 4,7-DOSA, 4-OSA, and 1B4E (the complex of E. coli PBGS and levulinic acid) structures shows that most of the
conformational change upon inhibitor binding occurs in the part of the
lid between positions 200 and 205. The deviation of the C
atoms in
this region does not exceed 1.4 Å, the side chain of
Arg204 is shifted approximately 2.5 Å away from the active
site to accommodate the A-side part of 4-OSA, and the other side chains
occupy very much the same positions in all three complexes.
The PBGS-catalyzed reaction involves significant hybridization changes
at multiple carbon centers (see Fig. 1). As described above, large
translational motion is not possible for the propionyl side chain of
P-side ALA. For A-side ALA, the C5 amino-containing portion appears
relatively fixed through interaction with the catalytic
Zn2+. This is apparent from prior 13C and
15N NMR data (26) and from the observation that the amino
group of the product porphobilinogen is chelated to the
Zn2+ in the unpublished human PBGS structure 1E51 and in
the complex of E. coli PBGS with
porphobilinogen.2 Thus, to
accommodate the significant hybridization changes, particularly at C3
of A-side ALA, the acetyl side chain must experience substantial mobility throughout the course of the reaction. One significant contribution of the current structure is the visualization of a
different orientation for the inhibitor atoms C6-C10 analogous to
C1-C5 of the A-side ALA. We propose that the observed multiple hydrogen bonds between the C10 carboxyl and Arg204,
Arg215, Gln219, and associated water molecules
change conformation to accommodate various positions of C1 and C2 of
A-side ALA during the course of the PBGS-catalyzed reaction.
A particularly vexing question in understanding the PBGS-catalyzed
reaction mechanism has been the identification of the residues that
serve as acceptors for the four protons and two oxygen atoms lost in
the condensation of two ALA molecules to porphobilinogen. The
contribution of these crystal structures to identifying the oxygen
acceptors is discussed above. The proton acceptor(s) for the
deprotonations of the amino group and C5 of P-side ALA appear to be the
two active site lysine residues as discussed previously (2).
Remarkably, there are no amino acids positioned to be the proton
acceptors at A-side ALA. Rather, comparison of these and other PBGS
structures shows a bath of highly conserved water molecules adjacent to
and including the Zn2+-bound water that initially derives
from C4 of A-side ALA. These water molecules are illustrated in Fig.
5A. Their positions are highly conserved, and they are
isolated from bulk solvent. These water molecules appear to be the only
possible acceptors for the protons that must be lost from A-side ALA.
The implication of water as the proton acceptor in the formation of an
enamine from an imine, akin to the removal of the first proton from C3
of A-side ALA, is not without precedent. Analogous chemistry has
recently been implicated in the mechanism of
D-2-deoxyribose-5-phosphate aldolase (27).
In summary, the PBGS-catalyzed reaction mechanism has been a subject of
debate for more than three decades. In fact, many different detailed
reaction mechanisms have been illustrated in the literature
(e.g. Refs. 2, 4-6, 18, 28-30), most of which do not
include a role for one or more essential metal ions. Basic features
such as the order of bond-making and bond-breaking reactions in the
PBGS-catalyzed reaction remains uncertain and may not be conserved for
all of the PBGS from different species. The current structures do not
resolve these uncertainties. However, the new structures of 4-OSA- and
4,7-DOSA-inhibited PBGS help identify the acceptor groups for the atoms
that are abstracted from the substrate molecules. They suggest that
enzyme-bound active site water molecules play pivotal roles in the
PBGS-catalyzed reaction and that there is a mechanistic importance to
fluctuations between multiple conformations of the active site lid.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Nicole Frankenberg, Robert
Petrovich, and Laura Mitchell for essential roles in purifying some of
the PBGS enzymes studied, Dr. Steven Seeholzer of the Biochemistry and
Biotechnology Facility for carrying out the mass spectral analyses, and
Professor Karen Allen of Boston University for helpful discussions.
 |
FOOTNOTES |
*
This work was supported by Grants ES03654 (to E. K. J.)
and CA06927 (to I. C. R.) from the NIEHS and NCI of the
National Institutes of Health and by an appropriation from the
Commonwealth of Pennsylvania.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The atomic coordinates and the structure factors (code 1L6S and 1L6Y) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
§
To whom correspondence should be addressed: Inst. for Cancer
Research, Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA
19111. Tel.: 215-728-3695; Fax: 215-728-2412; E-mail:
EK_Jaffe@fccc.edu.
¶
Present address: 3-Dimensional Pharmaceuticals, Inc., 665 Stockton Dr., Ste. 104, Exton, PA 19341.
**
Present address: Novartis Pharma Basel, P.O. Box, Basel 4002, Switzerland.
Published, JBC Papers in Press, March 21, 2002, DOI 10.1074/jbc.M201486200
2
H. L. Carrell, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
PBGS, porphobilinogen synthase;
ALA, 5-aminolevulinic acid;
ME, 2-mercaptoethanol;
4-OSA, 4-oxosebacic acid;
4, 7-DOSA,
4,7-dioxosebacic acid;
RMS, root mean-squared;
PDB, protein data bank;
A-side, acetyl side;
P-side, propionyl side.
 |
REFERENCES |
| 1.
|
Jaffe, E. K.
(2000)
Acta Crystallogr. Sect. D
56,
115-128[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Erskine, P. T.,
Norton, E.,
Cooper, J. B.,
Lambert, R.,
Coker, A.,
Lewis, G.,
Spencer, P.,
Sarwar, M.,
Wood, S. P.,
Warren, M. J.,
and Shoolingin-Jordan, P. M.
(1999)
Biochemistry
38,
4266-4276[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Kervinen, J.,
Jaffe, E. K.,
Stauffer, F.,
Neier, R.,
Wlodawer, A.,
and Zdanov, A.
(2001)
Biochemistry
40,
8227-8236[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Stauffer, F.,
Zizzari, E.,
Soldermann-Pissot, C.,
Faurite, J.-P.,
and Neier, R.
(2001)
Chimia
55,
314-319
|
| 5.
|
Erskine, P. T.,
Coates, L.,
Newbold, R.,
Brindley, A. A.,
Stauffer, F.,
Wood, S. P.,
Warren, M. J.,
Cooper, J. B.,
Shoolingin-Jordan, P. M.,
and Neier, R.
(2001)
FEBS Lett.
503,
196-200[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Jarret, C.,
Stauffer, F.,
Henz, M. E.,
Marty, M.,
Luond, R. M.,
Bobalova, J.,
Schurmann, P.,
and Neier, R.
(2000)
Chem. Biol.
7,
185-196[Medline]
[Order article via Infotrieve]
|
| 7.
|
Kervinen, J.,
Dunbrack, R. L., Jr.,
Litwin, S.,
Martins, J.,
Scarrow, R. C.,
Volin, M.,
Yeung, A. T.,
Yoon, E.,
and Jaffe, E. K.
(2000)
Biochemistry
39,
9018-9029[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Petrovich, R. M.,
Litwin, S.,
and Jaffe, E. K.
(1996)
J. Biol. Chem.
271,
8692-8699[Abstract/Free Full Text]
|
| 9.
|
Frankenberg, N.,
Heinz, D. W.,
and Jahn, D.
(1999)
Biochemistry
38,
13968-13975[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Jaffe, E. K.,
Volin, M.,
Bronson-Mullins, C. R.,
Dunbrack, R. L., Jr.,
Kervinen, J.,
Martins, J.,
Quinlan, J. F., Jr.,
Sazinsky, M. H.,
Steinhouse, E. M.,
and Yeung, A. T.
(2000)
J. Biol. Chem.
275,
2619-2626[Abstract/Free Full Text]
|
| 11.
|
Mitchell, L. W.,
and Jaffe, E. K.
(1993)
Arch. Biochem. Biophys.
300,
169-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Frankenberg, N.,
Jahn, D.,
and Jaffe, E. K.
(1999)
Biochemistry
38,
13976-13982[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Jaffe, E. K.,
Martins, J., Li, J.,
Kervinen, J.,
and Dunbrack, R. L., Jr.
(2001)
J. Biol. Chem.
276,
1531-1537[Abstract/Free Full Text]
|
| 14.
|
Copeland, R.,
Lombardo, D.,
Giannaras, J.,
and Decicco, C.
(1995)
Bioorg. Med. Chem. Lett.
5,
1947-1952[CrossRef]
|
| 15.
|
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326
|
| 16.
|
Brunger, A. T.,
Adams, P. D.,
Clore, G. M.,
DeLano, W. L.,
Gros, P.,
Grosse-Kunstleve, R. W.,
Jiang, J.-S.,
Kuszewski, J.,
Nilges, M.,
Pannu, N. S.,
Read, R. J.,
Rice, L. M.,
Simonson, T.,
and Warren, G. L.
(1998)
Acta Crystallogr. Sect. D
54,
905-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Jones, T. A.,
Zou, J. Y.,
Cowan, S.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. Sect. A
47,
110-119
|
| 18.
|
Jordan, P. M.,
and Seehra, J. S.
(1980)
J. Chem. Soc. Chem. Commun.
5,
240-242
|
| 19.
|
Jaffe, E. K.,
and Hanes, D.
(1986)
J. Biol. Chem.
261,
9348-9353[Abstract/Free Full Text]
|
| 20.
|
Frankenberg, N.,
Erskine, P. T.,
Cooper, J. B.,
Shoolingin-Jordan, P. M.,
Jahn, D.,
and Heinz, D. W.
(1999)
J. Mol. Biol.
289,
591-602[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Wynn, R.,
Harkins, P. C.,
Richards, F. M.,
and Fox, R. O.
(1996)
Protein Sci.
5,
1026-1031[Abstract]
|
| 22.
|
Erskine, P. T.,
Newbold, R.,
Brindley, A. A.,
Wood, S. P.,
Shoolingin-Jordan, P. M.,
Warren, M. J.,
and Cooper, J. B.
(2001)
J. Mol. Biol.
312,
133-141[Medline]
[Order article via Infotrieve]
|
| 23.
|
Spencer, P.,
and Jordan, P. M.
(1995)
Biochem. J.
305,
151-158
|
| 24.
|
Jaffe, E. K.
(1995)
J. Bioenerg. Biomembr.
27,
169-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Bock, C. W.,
Katz, A. K.,
Markham, G. D.,
and Glusker, J. P.
(1999)
J. Am. Chem. Soc.
121,
7360-7372[CrossRef]
|
| 26.
|
Jaffe, E. K.,
Markham, G. D.,
and Rajagopalan, J. S.
(1990)
Biochemistry
29,
8345-8350[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Heine, A.,
DeSantis, G.,
Luz, J. G.,
Mitchell, M.,
Wong, C.-H.,
and Wilson, I. A.
(2001)
Science
294,
369-374[Abstract/Free Full Text]
|
| 28.
|
Nandi, D. L.,
and Shemin, D.
(1968)
J. Biol. Chem.
243,
1236-1242[Abstract/Free Full Text]
|
| 29.
|
Barnard, G. F.,
Itoh, R.,
Hohberger, L. H.,
and Shemin, D.
(1977)
J. Biol. Chem.
252,
8965-8974[Free Full Text]
|
| 30.
|
Neier, R.
(1996)
Advances in Nitrogen Heterocycles
, Vol. 2
, pp. 35-146, JAI Press, Greenwich, CT
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Tang, L. Stith, and E. K. Jaffe
Substrate-induced Interconversion of Protein Quaternary Structure Isoforms
J. Biol. Chem.,
April 22, 2005;
280(16):
15786 - 15793.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. E. G. Muller, V. A. Grebenjuk, N. L. Thakur, A. N. Thakur, R. Batel, A. Krasko, I. M. Muller, and H. J. Breter
Oxygen-Controlled Bacterial Growth in the Sponge Suberites domuncula: toward a Molecular Understanding of the Symbiotic Relationships between Sponge and Bacteria
Appl. Envir. Microbiol.,
April 1, 2004;
70(4):
2332 - 2341.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Kundrat, J. Martins, L. Stith, R. L. Dunbrack Jr., and E. K. Jaffe
A Structural Basis for Half-of-the-sites Metal Binding Revealed in Drosophila melanogaster Porphobilinogen Synthase
J. Biol. Chem.,
August 15, 2003;
278(33):
31325 - 31330.
[Abstract]
[Full Text]
[PDF]
|
 |
|